Insulin-like growth factor 2 mRNA-binding protein 1 promotes cell proliferation via activation of AKT and is directly targeted by microRNA-494 in pancreatic cancer

Figure 6 MiR-494 reexpression partly abrogates the oncogenic effect of insulin-like growth factor 2 mRNA-binding protein 1 in pancreatic cancer. A: Enhanced cell viability of Mia PaCa-2 cells due to insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) overexpression was partly reduced following the reexpression of miR-494, which was detected by CCK-8 assays; B: Cell apoptosis was analyzed by flow cytometry when IGF2BP1-overexpressing Mia PaCa-2 cells were cotransfected with miR-494 mimics or their corresponding controls; C: The cell cycle was analyzed by flow cytometry when IGF2BP1-overexpressing Mia PaCa-2 cells were co-transfected with miR-494 mimics or control; D: Western blot analysis of AKT and p-AKT (Ser473) expression in the indicated cells and their corresponding control group; E: Correlations between the expression of miR-494 and IGF2BP1 in 30 pancreatic cancer specimens were determined by Pearson's correlation analysis; F: Kaplan-Meier analysis indicated that low miR-494 expression predicts a poorer overall survival rate than high miR-494 expression. All data are expressed as the mean ± standard deviation from three independent experiments at least and P < 0.05 was considered statistically significant. ^aP < 0.05 vs IGF2BP1-OE + miR-494 group at day 3; ^bP < 0.05 vs IGF2BP1-OE + miR-494 group at day 4; ^cP < 0.05 vs IGF2BP1-OE + miR-494 group at day 5; ^dP < 0.01 vs IGF2BP1-OE + miR-494 group; ^eP < 0.05 vs IGF2BP1-OE + miR-494 group. IGF2BP1: Insulin-like growth factor 2 mRNA-binding protein 1; 3’-UTR: 3’-untranslated region; Wt: Wild-type; Mut: Mutated.